Hint mode is switched on Switch off
For swift navigation between sections

Ardelyx

PDF download

Choose all Reset all
Download Cancel
Organization name
Ardelyx, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

19/02/2026 Ardelyx: , Including Exhibit 99.1 Hereto, Shall Not Be Considered “filed” Under The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Nor Shall It Be Incorporated By Reference Into Any Future Filing Under The Securities Act Of 1933, As Amended (the “securities Act”), Or Underthe Exchange Act, Unless The Company Expressly Sets Forth In Such Future Filing That Such Information Is To Be Considered “filed” Or Incorporated By Reference Therein, Regulation Fd Disclosure, Financial Statements And Exhibits
09/01/2026 Ardelyx, Inc. (NASDAQ:ARDX) Receives "Strong Buy" Rating from Raymond James
08/01/2026 Ardelyx: Is Incorporated Into This Item 8.01 By Reference, Financial Statements And Exhibits
03/01/2026 Raymond James Reaffirms Strong Buy on Ardelyx After Drug Price Increases
01/08/2025 Ardelyx: Shall Not Be Considered “filed” Under The Securities Exchange Act Of 1934, As Amended, Nor Shall It Be Incorporated By Reference Into Any Future Filing Under The Securities Act Of 1933, As Amended, Or Underthe Securities Exchange Act Of 1934, As Amended, Unless The Company Expressly Sets Forth In Such Future Filing That Such Information Is To Be Considered “filed” Or Incorporated By Reference Therein, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001437402
Registration is required to get access.